NewEdge Advisors LLC Has $84,000 Stake in Bruker Co. (NASDAQ:BRKR)

NewEdge Advisors LLC cut its stake in shares of Bruker Co. (NASDAQ:BRKR) by 69.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,429 shares of the medical research company’s stock after selling 3,250 shares during the quarter. NewEdge Advisors LLC’s holdings in Bruker were worth $84,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company’s stock valued at $118,081,000 after purchasing an additional 20,273 shares during the period. FIL Ltd grew its stake in Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock valued at $114,978,000 after acquiring an additional 1,420,102 shares during the period. Vaughan Nelson Investment Management L.P. increased its holdings in shares of Bruker by 140.3% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after acquiring an additional 666,617 shares in the last quarter. Norges Bank acquired a new position in shares of Bruker during the fourth quarter worth approximately $63,378,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Bruker by 7.6% in the 4th quarter. Bank of New York Mellon Corp now owns 988,863 shares of the medical research company’s stock worth $57,967,000 after purchasing an additional 69,806 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BRKR has been the subject of a number of analyst reports. Barclays cut their price target on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Wells Fargo & Company dropped their price objective on Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, April 17th. Stifel Nicolaus lowered their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a report on Friday, February 14th. Citigroup cut their target price on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Finally, Guggenheim restated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and an average target price of $65.00.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $40.44 on Friday. The company has a 50 day moving average of $42.05 and a 200 day moving average of $51.89. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 12 month low of $34.10 and a 12 month high of $79.78. The stock has a market cap of $6.13 billion, a P/E ratio of 53.21, a P/E/G ratio of 2.16 and a beta of 1.23.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, sell-side analysts forecast that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were given a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. Bruker’s payout ratio is 26.32%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.